Last reviewed · How we verify
C-CAR168
At a glance
| Generic name | C-CAR168 |
|---|---|
| Sponsor | AbelZeta Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease (PHASE1, PHASE2)
- A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy (PHASE1)
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |